Modality
mAb
MOA
KRASG12Di
Target
RET
Pathway
mTOR
DLBCLRCCFabry
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ Oct 2029
Phase 2Current
NCT08320859
2,565 pts·RCC
2020-05→2029-10·Completed
NCT06323576
2,082 pts·Fabry
2025-10→2029-05·Terminated
4,647 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-05-043.1y awayPh2 Data· Fabry
2029-10-043.5y awayPh2 Data· RCC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Complet…
P2
Termina…
Catalysts
Ph2 Data
2029-05-04 · 3.1y away
Fabry
Ph2 Data
2029-10-04 · 3.5y away
RCC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08320859 | Phase 2 | RCC | Completed | 2565 | HbA1c |
| NCT06323576 | Phase 2 | Fabry | Terminated | 2082 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |